+ND Capital

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

SBA Materials, Inc. is a company focused on the development and commercialization of advanced electronic materials specifically for back-end line and packaging applications in semiconductor manufacturing. Founded in 2001 and based in Albuquerque, New Mexico, the company specializes in low-k dielectric materials for interlayer dielectric applications, addressing critical needs in the semiconductor industry. Its product portfolio includes uLK22, uLK1X, optical films, and various nano-porous and meso-porous materials. These materials are designed with exceptional surface areas and can be chemically functionalized, enabling a broad range of applications from electronics to optics and sensors. The company operates from a facility within the Science and Technology Park, which houses research and development laboratories, offices, and meeting spaces, fostering innovation and collaboration with local institutions, including the University of New Mexico and Sandia National Laboratories.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.